1.2M
Downloads
942
Episodes
Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com
Episodes
Friday Jul 26, 2024
Friday Jul 26, 2024
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Location matters; Geo-rheumatology?
Friday Jul 19, 2024
Friday Jul 19, 2024
This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.
Friday Jul 12, 2024
Friday Jul 12, 2024
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Saturday Jul 06, 2024
Saturday Jul 06, 2024
Dr. Jack Cush reviews the terms in rheumatology that should no longer be used in the field of rheumatology. This lecture is part of the RheumNow Live 2024 meeting, being held January 27-28, 2024 in Dallas, TX (and virtually).
Friday Jun 28, 2024
Friday Jun 28, 2024
Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com
Monday Jun 24, 2024
Monday Jun 24, 2024
Moderated by Dr. Jack Cush and featuring Drs. Aurelie Najm, David Liew and Jonathan Kay
Monday Jun 24, 2024
Monday Jun 24, 2024
Monday Jun 24, 2024
Moderated by Dr. Jack Cush and Featuring Drs. Eric Ruderman, Antoni Chan, and Peter Nash
Friday Jun 21, 2024
Friday Jun 21, 2024
Featuring Drs. Artie Kavanaugh and Jack Cush Discussion of highlights from the EULAR 2024 Meeting in Vienna
Tuesday Jun 18, 2024
Tuesday Jun 18, 2024
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:
OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Giant Cell Arteritis and Polymyalgia Rheumatica Update
Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria.
JAK Inhibitors for New Indications
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
Pain in RA: Different Drugs for Different Mechanisms
Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086.
Top 3 Messages About JAK Inhibitor Safety
Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety.
DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop
Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria.
Has JAK POT Hit the Spot About Infection Risk?
Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria.
Select your GCA Therapy
Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.